FIELD: biotechnology.
SUBSTANCE: invention relates to proteins and polynucleotides, which stimulate enzyme cleavage and releasing of TNF receptors. Also disclosed are methods for identification of additional agents, which influence on TNF receptor releasing from cells. Products of present invention containing in pharmaceutical compositions as active ingredients increase or decrease TNF signal transduction and consequently abate disease pathology.
EFFECT: new pharmaceutical compositions.
27 cl, 8 ex, 3 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| ERYTHROFERRONE AND ERFE POLYPEPTIDES AND METHODS FOR REGULATING IRON METABOLISM | 2013 |
|
RU2684216C2 |
| METHODS FOR BONE CANCER RELATED PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST | 2005 |
|
RU2389509C2 |
| METHODS OF OSTEOARTHRITIS PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING IT | 2006 |
|
RU2429013C2 |
| INFLUENZA HAEMAGGLUTININ AND NEURAMINIDASE VARIANTS | 2010 |
|
RU2535970C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
